Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Long-term Extension Study of KRN23 in Patients with X-linked Hypophosphatemic Rickets/Osteomalacia and a Post-marketing Study of KRN23 Switched from the Phase 3 Long-term Extension Study

Next Previous
Trial Profile

Phase 3 Long-term Extension Study of KRN23 in Patients with X-linked Hypophosphatemic Rickets/Osteomalacia and a Post-marketing Study of KRN23 Switched from the Phase 3 Long-term Extension Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Burosumab (Primary)
  • Indications Osteomalacia; X-linked dominant hypophosphataemic rickets
  • Focus Adverse reactions
  • Sponsors Kyowa Kirin

Most Recent Events

  • 07 Feb 2023 New trial record
  • 31 Jan 2023 Results from NCT03233126 and NCT04308096, assessing efficacy and safety of burosumab when administered either by a carer or patient , published in the Advances in Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top